Loading...
•
Mar 31, 2022
Roivant Sciences Q4 2022 Earnings Report
Roivant Sciences reported financial results and provided a business update.
Key Takeaways
Roivant Sciences reported a net loss of $291.3 million for the quarter ended March 31, 2022. The company had $2.1 billion in cash and cash equivalents as of March 31, 2022. VTAMA was approved by the FDA for the treatment of plaque psoriasis.
VTAMA approved by FDA for the treatment of plaque psoriasis.
Priovant established in partnership with Pfizer to develop brepocitinib for autoimmune diseases.
Roivant reported $2.1B in cash and cash equivalents.
Early discovery efforts validated with multiple collaborations.
Forward Guidance
Roivant expects to provide updates on the commercial launch of VTAMA for psoriasis and report topline data from the Phase 3 clinical trials of VTAMA for the treatment of atopic dermatitis in the first half of calendar year 2023.
Positive Outlook
- Dermavant expects to provide updates on the commercial launch of VTAMA® for psoriasis on a periodic basis
- Dermavant expects to report topline data from the Phase 3 clinical trials of VTAMA® for the treatment of atopic dermatitis in the first half of calendar year 2023
- Immunovant plans to initiate two Phase 3 trials to evaluate batoclimab for the treatment of thyroid eye disease in the second half of calendar year 2022, with topline results expected in the first half of calendar year 2025
- Immunovant also plans to initiate an additional Phase 3 trial in another indication in the second half of calendar year 2022 and announce two new indications by August 2022
- Results from the additional cohorts of the batoclimab and atorvastatin drug-drug interaction study are expected to be available by the end of calendar year 2022
Challenges Ahead
- All product candidates referenced in this press release are investigational and subject to health authority approval.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...